Compare SEGG & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEGG | MYNZ |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | Germany |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.8M |
| IPO Year | 2023 | 2021 |
| Metric | SEGG | MYNZ |
|---|---|---|
| Price | $1.02 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | N/A | ★ 195.9K |
| Earning Date | N/A | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $0.92 |
| 52 Week High | N/A | $8.20 |
| Indicator | SEGG | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 53.19 |
| Support Level | $0.84 | $1.09 |
| Resistance Level | $0.99 | $1.29 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 26.40 | 60.56 |
Lottery.com Inc is a provider of domestic and international lottery products and services. As an independent third-party lottery game service, the Company offers a platform that it developed and operates to enable the remote purchase of legally sanctioned lottery games in the U.S. and abroad. The Company's revenue-generating activities are focused on (i) offering the Platform via the Lottery.com app and its websites to users located in the U.S. and international jurisdictions where the sale of lottery games is legal and its services are enabled for the remote purchase of legally sanctioned lottery games; (ii) offering an internally developed, created and operated business-to-business application programming interface of the Platform to enable commercial partners in permitted U.S.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.